Paper4771975
Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia.
Dombernowsky P and 1 other. Acta Pathol Microbiol Scand A, 1973. Cited by 170 papers, by iCite.
Cite this record
ConductScience Library. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia. Papers, record 4771975. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4771975
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia L1210 | Major topic |
| Podophyllotoxin | Major topic |
| Animals | |
| Drug Evaluation, Preclinical | |
| Female | |
| Injections, Intraperitoneal | |
| Male | |
| Mice | |
| Neoplasm Transplantation | |
| Time Factors | |
| Transplantation, Homologous |
Source PubMed
Cited by37
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 170 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 33921719 | Podophyllotoxin: History, Recent Advances and Future Prospects. | Biomolecules | 2021 | https://conductscience.org/library/papers/33921719 | PubMed |
| 22993597 | Inhibition of tumor angiogenesis by oral etoposide. | Exp Ther Med | 2010 | https://conductscience.org/library/papers/22993597 | PubMed |
| 15356657 | Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse. | Leukemia | 2004 | https://conductscience.org/library/papers/15356657 | PubMed |
| 15139794 | Pharmacokinetic optimisation of treatment with oral etoposide. | Clin Pharmacokinet | 2004 | https://conductscience.org/library/papers/15139794 | PubMed |
| 10711842 | Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues. | Drugs | 1999 | https://conductscience.org/library/papers/10711842 | PubMed |
| 9667675 | Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer. | Br J Cancer | 1998 | https://conductscience.org/library/papers/9667675 | PubMed |
| 8609070 | Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer. | Jpn J Cancer Res | 1996 | https://conductscience.org/library/papers/8609070 | PubMed |
| 8174207 | Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/8174207 | PubMed |
| 8137464 | Chronic oral etoposide in advanced breast cancer. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/8137464 | PubMed |
| 8075006 | Multilevel therapeutic targeting by topoisomerase inhibitors. | Br J Cancer Suppl | 1994 | https://conductscience.org/library/papers/8075006 | PubMed |
| 8070033 | Schedule-dependent topoisomerase II-inhibiting drugs. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/8070033 | PubMed |
| 8070031 | Etoposide dosage and pharmacodynamics. | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/8070031 | PubMed |
| 8070017 | Prolonged administration of low-daily-dose etoposide: a superior dosing schedule? | Cancer Chemother Pharmacol | 1994 | https://conductscience.org/library/papers/8070017 | PubMed |
| 7947097 | Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells. | Br J Cancer | 1994 | https://conductscience.org/library/papers/7947097 | PubMed |
| 7781140 | Safety and efficacy of intraperitoneal injection of etoposide in oil suspension in mice with peritoneal carcinomatosis. | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7781140 | PubMed |
| 7554043 | Etoposide protein binding in cancer patients. | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7554043 | PubMed |
| 7539339 | Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7539339 | PubMed |
| 7083457 | A phase I trial of continuous infusion VP16-213 (etoposide). | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7083457 | PubMed |
| 7044594 | VP16-213 (etoposide). A critical review of its activity. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7044594 | PubMed |
| 7031350 | [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)]. | Klin Wochenschr | 1981 | https://conductscience.org/library/papers/7031350 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4771975
GET https://conductscience.org/api/papers/v1/4771975/cited_by?page=2